$INTI
Inhibitor Therapeutics, Inc.

2016 Q2 Form 10-Q Financial Statement

#000119312516589701 Filed on May 13, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $720.0K $610.0K $610.0K
YoY Change 46.94% 0.0% 281.25%
% of Gross Profit
Research & Development $605.5K $582.5K $313.0K
YoY Change 101.65% 86.1% 1136.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.330M $1.194M $922.7K
YoY Change 68.01% 29.46% 393.59%
Operating Profit -$1.330M -$1.194M -$922.7K
YoY Change 68.01% 29.46% 393.59%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.330M -$1.190M -$920.0K
YoY Change 68.35% 29.35% 360.0%
Income Tax
% Of Pretax Income
Net Earnings -$1.329M -$1.194M -$922.7K
YoY Change 67.88% 29.46% 369.58%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 268.4M shares 245.4M shares 211.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.620M $120.0K $80.00K
YoY Change 144.44% 50.0%
Cash & Equivalents $4.615M $118.6K $83.95K
Short-Term Investments
Other Short-Term Assets $50.22K $52.02K $43.72K
YoY Change 0.44% 18.97% 337.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.665M $170.6K $127.7K
YoY Change 140.5% 33.65% 1121.06%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $250.0K $250.0K
YoY Change 0.0%
Total Long-Term Assets $250.0K $250.0K $0.00
YoY Change 0.0%
TOTAL ASSETS
Total Short-Term Assets $4.665M $170.6K $127.7K
Total Long-Term Assets $250.0K $250.0K $0.00
Total Assets $4.915M $420.6K $127.7K
YoY Change 124.46% 229.46% 1121.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $396.0K $647.1K $493.9K
YoY Change 60.69% 31.03% 39.08%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $618.1K $743.4K $568.6K
YoY Change 49.77% 30.76% -41.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $618.1K $743.4K $568.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $618.1K $743.4K $568.6K
YoY Change 49.77% 30.76% -41.38%
SHAREHOLDERS EQUITY
Retained Earnings -$38.70M -$37.37M -$33.15M
YoY Change 14.02% 12.74% 16.53%
Common Stock $42.99M $37.04M $32.70M
YoY Change 20.38% 13.27% 1731225.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.297M -$322.8K -$440.9K
YoY Change
Total Liabilities & Shareholders Equity $4.915M $420.6K $127.7K
YoY Change 124.46% 229.46% 1121.06%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$1.329M -$1.194M -$922.7K
YoY Change 67.88% 29.46% 369.58%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.010M -$480.0K -$280.0K
YoY Change 46.38% 71.43% 154.55%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.500M 0.000
YoY Change 120.0% -100.0%
NET CHANGE
Cash From Operating Activities -1.010M -480.0K -280.0K
Cash From Investing Activities
Cash From Financing Activities 5.500M 0.000
Net Change In Cash 4.490M -480.0K -280.0K
YoY Change 148.07% 71.43%
FREE CASH FLOW
Cash From Operating Activities -$1.010M -$480.0K -$280.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
268393270 shares
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83951
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
245353270 shares
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
245353270 shares
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
37019678
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
-322790
CY2016Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
96316
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
647114
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-37367003
CY2016Q1 us-gaap Liabilities
Liabilities
743430
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
420640
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
24535
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
743430
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2016Q1 us-gaap Assets
Assets
420640
CY2016Q1 us-gaap Assets Current
AssetsCurrent
170640
CY2016Q1 us-gaap Other Assets Current
OtherAssetsCurrent
52017
CY2016Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0
CY2016Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118623
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
365161
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
245353270 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
245353270 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36571982
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
423979
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
78524
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
383356
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36172538
CY2015Q4 us-gaap Liabilities
Liabilities
461880
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
885859
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
24535
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
461880
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2015Q4 us-gaap Assets
Assets
885859
CY2015Q4 us-gaap Assets Current
AssetsCurrent
635859
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
34414
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
601445
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-281210
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
211419937 shares
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-922674
CY2015Q1 us-gaap Revenues
Revenues
0
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-54094
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
419703
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-281210
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
922674
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
313017
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
609657
CY2015Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
167667
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-482822
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
CY2016Q1 dei Trading Symbol
TradingSymbol
HPPI
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
245353270 shares
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P29M
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-1194465
CY2016Q1 us-gaap Revenues
Revenues
0
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
17603
CY2016Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
447696
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
447696
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-482822
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
1194465
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
582513
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
611952
CY2016Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
281550

Files In Submission

Name View Source Status
0001193125-16-589701-index-headers.html Edgar Link pending
0001193125-16-589701-index.html Edgar Link pending
0001193125-16-589701.txt Edgar Link pending
0001193125-16-589701-xbrl.zip Edgar Link pending
d172725d10q.htm Edgar Link pending
d172725dex311.htm Edgar Link pending
d172725dex312.htm Edgar Link pending
d172725dex321.htm Edgar Link pending
d172725dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20160331.xml Edgar Link completed
hppi-20160331.xsd Edgar Link pending
hppi-20160331_cal.xml Edgar Link unprocessable
hppi-20160331_def.xml Edgar Link unprocessable
hppi-20160331_lab.xml Edgar Link unprocessable
hppi-20160331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending